Ann: ATL1102 DMD Clinical Trial Application Submitted in Europe, page-51

There is a lot of validity to this comment. The SP is being weighted down due to medium term funding uncertainty. Whether a CR is done after the next raft of scientific announcemts hopefully appreciates the SP or whether it’s done right away at say a 20% discount to our current paltry SP doesn’t particularly fuss me. Uncertainty is the killer. I am truly despairing at this company’s lack of commerciality & corporate direction- as evidenced by the insipid commercial /$$ words in the recent Ann. 3rd rate advice written over everything.